Generation of a Primary Hyperoxaluria Type 1 Disease Model Via CRISPR/Cas9 System in Rats

Author(s): Rui Zheng, Xiaoliang Fang, Lei He, Yanjiao Shao, Nana Guo, Liren Wang, Mingyao Liu, Dali Li*, Hongquan Geng*.

Journal Name: Current Molecular Medicine

Volume 18 , Issue 7 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


Background: Primary hyperoxaluria type 1 (PH1) is an inherited disease caused by mutations in alanine-glyoxylate aminotransferase (AGXT). It is characterized by abnormal metabolism of glyoxylic acid in the liver leading to endogenous oxalate overproduction and deposition of oxalate in multiple organs, mainly the kidney. Patients of PH1 often suffer from recurrent urinary tract stones, and finally renal failure. There is no effective treatment other than combined liver-kidney transplantation.

Methods: Microinjection was administered to PH1 rats. Urine samples were collected for urine analysis. Kidney tissues were for Western blotting, quantitative PCR, AGT assays and histological evaluation.

Results: In this study, we generated a novel PH1 disease model through CRISPR/Cas9 mediated disruption of mitochondrial localized Agxt gene isoform in rats. Agxt-deficient rats excreted more oxalate in the urine than WT animals. Meanwhile, mutant rats exhibited crystalluria and showed a slight dilatation of renal tubules with mild fibrosis in the kidney. When supplied with 0.4% ethylene glycol (EG) in drinking water, mutant rats excreted greater abundance of oxalate and developed severe nephrocalcinosis in contrast to WT animals. Significantly elevated expression of inflammation- and fibrosisrelated genes was also detected in mutants.

Conclusion: These data suggest that Agxt-deficiency in mitochondria impairs glyoxylic acid metabolism and leads to PH1 in rats. This rat strain would not only be a useful model for the study of the pathogenesis and pathology of PH1 but also a valuable tool for the development and evaluation of innovative drugs and therapeutics.

Keywords: Primary hyperoxaluria type 1, nephrocalcinosis, CRISPR/Cas9, kidney, gene editing, mitochondria.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [436 - 447]
Pages: 12
DOI: 10.2174/1566524019666181212092440
Price: $65

Article Metrics

PDF: 26